Correction: COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States

Wang, Quan Qiu; Kaelber, David C.; Xu, Rong; Volkow, Nora D.

doi:10.1038/s41380-020-00895-0

Cited by 38 publications

(54 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hospitalization rates were also higher among those older than 40 years and those with documented history of injection drug use; the latter finding was also observed in a national, non–HIV-focused case-control study. 38 …”

Section: Discussionmentioning

confidence: 99%

COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State

et al. 2021

View full text Add to dashboard Cite

Key Points Question Is there an association between prior diagnosis of HIV infection and coronavirus disease 2019 (COVID-19) diagnosis, hospitalization, and in-hospital death among residents of New York State? Findings In a cohort study of linked statewide HIV diagnosis, COVID-19 laboratory diagnosis, and hospitalization databases, persons living with an HIV diagnosis were more likely to receive a diagnosis of, be hospitalized with, and die in-hospital with COVID-19 compared with those not living with an HIV diagnosis. After demographic adjustment, COVID-19 hospitalization remained significantly elevated for individuals with an HIV diagnosis and was associated with elevated mortality. Meaning Persons living with an HIV diagnosis experienced poorer COVID-related outcomes (principally, higher rates of severe disease requiring hospitalization) relative to those without an HIV diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, the exact effect of chronic use of the same opioids on angiotensin II binding and interleukin levels has not been well established. What is clear is that patients with opioid use disorder are at higher risk of contracting and developing severe COVID-19 disease [12].…”

Section: Main Bodymentioning

confidence: 99%

“…Clinically speaking, opioid use disorder may increase the disease's complications and severity or modulate cytokine storms and be beneficial. However, epidemiological evidence, so far available, indicates a higher susceptibility of patients with opioid use disorder in contracting COVID-19 disease and having more severe and detrimental effects [12]. At this time, it is hard to distinguish whether it is the comorbidities or the immunological impact of opioids that are responsible for a more severe course of COVID-19 in patients with opioid use disorder.…”

Section: Main Bodymentioning

confidence: 99%

“…Accordingly, a randomized clinical trial reported that both methadone and partial mu agonists, such as buprenorphine, could activate the immune systems in people who use heroin [38]. A recent study that evaluated the risks and outcomes for COVID-19 in people with substance use disorders (SUD) indicates that medications used to treat opioid use disorder (OUD) had no significant effects on patients' risk for COVID-19 after adjusting for age, gender, race, and insurance type [12].…”

Section: Main Bodymentioning

confidence: 99%

“…Epidemiologic studies have shown an increase in mortality rate in people with opioid use disorder with COVID-19 during the pandemic. For example, Wang et al demonstrated that people with substance use disorder, particularly recent opioid use disorders, are at higher risk for COVID-19 (adjusted odds ratio = 10.244 [9.10-11.52], P < 10 − 30 ) and worse outcomes (death: 9.6%, hospitalization: 41.0%, P < 0.05) [12].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A double-edged sword of using opioids and COVID-19: a toxicological view

Ataei

Shirazi

Lamarine

et al. 2020

Subst Abuse Treat Prev Policy

View full text Add to dashboard Cite

Today, COVID-19 is spreading around the world. Information about its mechanism, prognostic factors, and management is minimal. COVID-19, as a human disease, has several identifying phases. Physicians of patients with COVID-19 may be interested in knowing whether opioid use disorder may affect their patients’ course or prognosis. This information may be crucial when considering the opioid epidemic in the US and other parts of the world. Opioid use at high doses and over several months duration can mitigate the immune system’s function, which may complicate the course of COVID-19 disease. Potential suppression of parts of the immune response may be important in prevention, clinical support, and therapeutic use of medications in various phases of the COVID-19. Specifically, opioid use disorders via an inhalation route may enhance the “late hyper-inflammatory phase” or result in end-organ damage. It is well established that opioids decrease ventilation as their effect on the medullary respiratory centers increases the risk of pneumonia. This increased risk has been associated with immune-suppressive opioids. The ultimate role of opioids in COVID-19 is not clear. This paper endorses the need for clinical studies to decipher the role and impact of chronic opioid use on viral diseases such as COVID-19.

show abstract

Immunotoxicology of Drugs of Abuse

Kaplan

2024

Reference Module in Biomedical Sciences

View full text Add to dashboard Cite

Correction: COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States

Cited by 38 publications

References 0 publications

COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State

COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State

A double-edged sword of using opioids and COVID-19: a toxicological view

Immunotoxicology of Drugs of Abuse

Contact Info

Product

Resources

About